Pharmafile Logo
Pharmafocus logo
Advanced Search

galcanezumab

Showing 1 posts of 1 posts found.

Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form

May 16, 2018
Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma

Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …

News
The Gateway to Local Adoption Series

Latest content

Care Quality Commission appoints Emily Miles as Chief Executive

July 17, 2026

National survey aims to improve glaucoma care across the UK

July 16, 2026

Phase 3 trials support expanded use of Dysport for migraine prevention

July 15, 2026

Roche secures CE Mark for automated latent tuberculosis blood test

July 14, 2026

ReproNovo Phase 2 fertility study doses first participant

July 10, 2026